We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
-$88M
Cap. Flow
-$194M
Cap. Flow %
-10.24%
Top 10 Hldgs %
47.92%
Holding
151
New
44
Increased
37
Reduced
36
Closed
31
Avg Time Held Equity + Options
1 year
Top 10 Avg Time Held Equity + Options
1.5 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1 year

Top Buys

Rank Stock Value
1
BKD icon
Brookdale Senior Living
BKD
+$44.7M
2
WELL icon
Welltower
WELL
+$35.8M
3
DOC icon
Healthpeak Properties
DOC
+$33.9M
4
ABVX icon
Abivax
ABVX
+$32.7M
5
OHI icon
Omega Healthcare
OHI
+$26.7M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$48.5M
2
DHR icon
Danaher
DHR
+$42.6M
3
VERA icon
Vera Therapeutics
VERA
+$38.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$31.7M
5
BRKR icon
Bruker
BRKR
+$27.9M

Sector Composition

Rank Sector Weight
1 Healthcare 74.35%
2 Miscellaneous 20.04%
3 Real Estate 5.59%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
UTHR icon
1
United Therapeutics
UTHR
$23.2B
$157M 8.26%
264,271
+11,679
+5% +$5.82M
2020 Q2
23 quarters
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$487B
$138M 7.26%
238,700
+13,700
+6% +$8.32M
2023 Q1
12 quarters
ABVX icon
3
Abivax
ABVX
$7.68B
$104M 5.49%
934,423
+276,589
+42% +$32.7M
2025 Q3
2 quarters
GSK icon
4
GSK
GSK
$98.2B
$98.5M 5.2%
1,785,175
-894,546
-33% -$48.5M
2018 Q1
32 quarters
VERA icon
5
Vera Therapeutics
VERA
$2.06B
$87.4M 4.61%
2,173,286
-899,018
-29% -$38.7M
2022 Q3
14 quarters
NTRA icon
6
Natera
NTRA
$58.3B
$76.9M 4.06%
384,713
+50,220
+15% +$10.8M
2022 Q2
15 quarters
SPY icon
7
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$69.6M 3.67%
107,000
+62,100
+138% +$42.2M
2025 Q4
1 quarter
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.22B
$67.4M 3.55%
2,885,622
-428,786
-13% -$9.32M
2022 Q2
15 quarters
CLDX icon
9
Celldex Therapeutics
CLDX
$2.27B
$56.7M 2.99%
1,788,016
+353,291
+25% +$9.63M
2021 Q4
17 quarters
PCVX icon
10
Vaxcyte
PCVX
$10.3B
$53.7M 2.83%
924,193
-273,529
-23% -$14.8M
2024 Q4
5 quarters
BKD icon
11
Brookdale Senior Living
BKD
$2.41B
$48.8M 2.57%
3,568,555
+3,193,626
+852% +$44.7M
2025 Q4
1 quarter
IONS icon
12
Ionis Pharmaceuticals
IONS
$7.33B
$47.5M 2.5%
632,100
+93,882
+17% +$7.41M
2021 Q2
19 quarters
VRTX icon
13
CALL
Vertex Pharmaceuticals
VRTX
$129B
$40.2M 2.12%
+90,000
New +$42M
2026 Q1
0 quarters
HCA icon
14
HCA Healthcare
HCA
$101B
$37.5M 1.98%
79,229
-16,645
-17% -$8.38M
2023 Q1
12 quarters
TLT icon
15
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$49.7B
$37.2M 1.96%
428,800
+198,800
+86% +$17.5M
2025 Q4
1 quarter
WELL icon
16
Welltower
WELL
$169B
$35.8M 1.89%
+180,953
New +$35.8M
2026 Q1
0 quarters
DOC icon
17
Healthpeak Properties
DOC
$13.1B
$32.5M 1.72%
+1,981,070
New +$33.9M
2026 Q1
0 quarters
PODD icon
18
Insulet
PODD
$9.62B
$30.1M 1.59%
143,546
+68,838
+92% +$17.3M
2025 Q3
2 quarters
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.05B
$28.9M 1.53%
3,039,820
+46,925
+2% +$364K
2022 Q4
13 quarters
GERN icon
20
Geron
GERN
$790M
$28.1M 1.48%
18,834,883
+1,174,900
+7% +$1.79M
2025 Q2
3 quarters
OHI icon
21
Omega Healthcare
OHI
$13.8B
$25.7M 1.35%
+585,680
New +$26.7M
2026 Q1
0 quarters
LQDA icon
22
Liquidia Corp
LQDA
$3.11B
$25.6M 1.35%
677,392
+167,949
+33% +$6.23M
2021 Q1
20 quarters
CYH icon
23
Community Health Systems
CYH
$422M
$25.5M 1.35%
8,677,281
+733,479
+9% +$2.38M
2020 Q4
21 quarters
AVTR icon
24
Avantor
AVTR
$10.9B
$23.3M 1.23%
2,974,287
-202,357
-6% -$1.99M
2023 Q3
10 quarters
QGEN icon
25
Qiagen
QGEN
$9.53B
$21.8M 1.15%
+545,330
New +$25.8M
2026 Q1
0 quarters
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Eversept Partners held 151 positions worth $1.9B, down 4.4% from $1.98B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Eversept Partners withdrew a net $194M in Q1 2026, closing 31 positions and reducing 36 holdings. Its most notable exit was Danaher, an estimated $42.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Eversept Partners opened a new position in Welltower worth $35.8M.

  • Eversept Partners's largest Q1 2026 buy was Welltower: 180,953 shares worth $35.8M.
  • Eversept Partners added most to Brookdale Senior Living in Q1 2026, an estimated $44.7M increase.
  • Eversept Partners's biggest Q1 2026 reduction was GSK, cutting an estimated $48.5M.
  • Eversept Partners fully exited Danaher in Q1 2026, selling an estimated $42.6M.
  • Eversept Partners's ten largest holdings make up 48% of its $1.9B portfolio in Q1 2026.
  • Eversept Partners opened 44 new positions and closed 31 in Q1 2026.
  • Eversept Partners's portfolio value fell 4.4% quarter-over-quarter to $1.9B.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.